Abstract

Caffeine has been reported to induce anti-tumor immunity for attenuating breast cancer by blocking the adenosine 2A receptor. Molecular modeling showed that theacrine, a purine alkaloid structurally similar to caffeine, might be an antagonist of the adenosine 2A receptor equivalent to or more effective than caffeine. Theacrine was further demonstrated to be an effective antagonist of the adenosine 2A receptor as its concurrent supplementation significantly reduced the elevation of AMPK phosphorylation level in MCF-7 human breast cells induced by CGS21680, an agonist of adenosine 2A receptors. In an animal model, the development of mammary carcinoma induced by 7,12-Dimethylbenz[a]anthracene in Sprague–Dawley rats could be attenuated by daily supplement of theacrine of 50 or 100 mg/kg body weight. Both expression levels of cleaved-caspase-3/pro-caspase-3 and granzyme B in tumor tissues were significantly elevated when theacrine was supplemented, indicating the induction of programmed cell death in tumor cells might be involved in the attenuation of mammary carcinoma. Similar to the caffeine, significant elevation of interferon-γ and tumor necrosis factor-α was observed in the serum and tumor tissues of rats after the theacrine supplement of 50 mg/kg body weight. Taken together, theacrine is an effective antagonist of adenosine 2A receptors and possesses great potential to be used to attenuate breast cancer.

Highlights

  • Regulation of the adenosine 2A receptor was proposed to be a prospective target for immunotherapy, and antagonists of the adenosine 2A receptor were demonstrated to be potential drugs to enhance the immunological response for the attenuation of the development of mammary carcinoma [7,8,9,10]

  • Putative signaling pathways induced by theacrine supplement were examined in MCF-7 human breast cells and an animal model of mammary carcinoma

  • The results showed that theacrine as well as caffeine and adenosine could get into and bind to the cavity of ADORA2A (Figure 1)

Read more

Summary

Introduction

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Regulation of the adenosine 2A receptor was proposed to be a prospective target for immunotherapy, and antagonists of the adenosine 2A receptor were demonstrated to be potential drugs to enhance the immunological response for the attenuation of the development of mammary carcinoma [7,8,9,10]. We speculated that theacrine might serve as an antagonist of the adenosine 2A receptor in a manner similar to caffeine, and that the potential usage of theacrine on breast cancer might be a result of the blocking of adenosine 2A receptor activation. Putative signaling pathways induced by theacrine supplement were examined in MCF-7 human breast cells and an animal model of mammary carcinoma

Results
Detecting Theacrine as an Antagonist of the Adenosine 2A Receptor
Effects of Theacrine on DMBA-Induced Mammary Carcinoma in Rats
Elevation of volume
Effects of Theacrine on the Levelsinoftumor
Discussion
Materials
Homology Modeling and Docking
Cell Culture
Cell Viability Assay
Animals
Estimation of Body and Tumor Parameters
Enzyme Linked Immune Sorbent Assay for Proinflammatory Cytokines
Western Blotting
Statistical Analysis
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call